Yamanouchi Deal Brings MediGene Breathing Space
Executive Summary
MediGene's recent licensing deal with Yamanouchi buys the German biotech time, but does little to strengthen its long-term finances. For this, MediGene will likely have to brave the cold waters of the German capital markets. It will be the first biotech to do so since Germany's growth market collapsed in 2001.You may also be interested in...
The Pan European Licensing Opportunity
Getting Late Stage Products Early
Senexis Ltd.
Need a specific report? 1000+ reports available
Buy Reports